Business
Notice of Full Year Results
Notice of Full Year Results.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 3446I Faron Pharmaceuticals Oy 21 March 2018 \n\n \nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nNotice of Full Year Results\n \nTURKU - FINLAND, 21 March 2018 - Faron Pharmaceuticals Ltd (\"Faron\") (AIM: FARN), the clinical stage biopharmaceutical company, will announce its full year audited results for the year ended 31 December 2017 on Tuesday 8 May 2018.\n \nDr Markku Jalkanen, Chief Executive Officer, and Yrjö Wichmann, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF. Please contact Consilium Strategic Communications for further details.\n \n \nENDS\n \nFor more information please contact:\n \nFaron Pharmaceuticals Ltd\nDr Markku Jalkanen, Chief Executive Officer\[email protected] \n \nConsilium Strategic Communications\nMary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville\nPhone: +44 (0)20 3709 5700\nE-mail: [email protected]\n \nPanmure Gordon (UK) Limited, Nomad and Broker\nFreddy Crossley, Ryan McCarthy (Corporate Finance)\nTom Salvesen, Amy Sarra (Corporate Broking)\nPhone: +44 207 886 2500\n \nWestwicke Partners, IR (US)\nChris Brinzey\nPhone: 01 339 970 2843\nE-Mail: [email protected]\n \n \nAbout Faron Pharmaceuticals Ltd \n \nFaron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (\"ARDS\") undergoing Phase III clinical trials with expected clinical read outs in 2018. In 2017 the Company received advice from US FDA to proceed directly to BLA submission following completion of EU and Japanese Phase III studies. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (\"RAAA\"). Faron's second candidate Clevegen is a ground br...